Calcium metabolism in sarcoidosis and its clinical implications

Rheumatology

Volumn 39, Issue 7, 2000, Pages 707-713

  Conron, M ^a   Young, C ^a   Beynon, H L C ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; THIAZIDE DIURETIC AGENT;

BONE DENSITY; CALCIUM HOMEOSTASIS; CALCIUM METABOLISM; HORMONE ACTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SARCOIDOSIS; SYNTHESIS;

EID: 0033931863     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.7.707     Document Type: Review

References (80)

1. Blood chemical changes in Boeck's sarcoid with particular reference to protein, calcium and phosphatase levels
2. Bone mineral content in sarcoidosis
3. Renal involvement in sarcoidosis
4. Abnormal calcium metabolism in sarcoidosis. La sarcoidose: Rapport IV Conference Internationale
5. Seasonal influence of sunlight on the hypercalcemia of sarcoidosis
6. Renal manifestations of sarcoidosis
7. Sarcoidosis with renal involvement
8. The kidney in sarcoidosis
9. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis
10. Rheumatoid arthritis, corticosteroid therapy and the risk of hip fracture
11. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids
12. Biosynthesis of membrane lipids and steroid hormones
13. Vitamin D
14. Unique biosynthesis by the kidney of a biologically active vitamin D metabolite
15. Vitamin D metabolite mediated hypercalcemia
16. Bone mineralization activity of 1,25-dihydroxyvitamin D
17. The remission of hypercalcemia and hypercalcuria in systemic sarcoidosis by vitamin D depletion
18. Evidence that increased circulating 25-dihydroxyvitamin D is the probable cause of abnormal calcium metabolism in sarcoidosis
19. Hypercalcemia in an anephric patient with sarcoidosis: Evidence for extrarenal generation of 1,25-dihydroxy-vitamin D
20. 3 in pregnancy
21. Metabolism of 25-hydroxyvitamin D by cultured pulmonary alveolar macrophages in sarcoidosis
22. Isolation and structural identification of 1,25-dihydroxyvitamin D produced by cultured alveolar macrophages in sarcoidosis
23. Vitamin D conversion by sarcoid lymph node homogenate
24. Abnormal regulation of 25-hydroxyvitamin D-1α-hydroxylase activity by calcium and calcitonin in renal cortex from hypophosphatemic mice
25. Regulation of 1,25-hydroxyvitamin D production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis
26. Potentiation of the macrophage 25-hydroxy vitamin D-1 hydroxylation reaction by human pleural effusion fluid
27. Vitamin D, endocrine and paracrine mediator in cases of pulmonary granulomatosis
28. Lung restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis
29. Pulmonary sarcoidosis: A disorder mediated by excess helper T-lymphocyte activity at sites of disease activity
30. Sarcoidosis: TNFα release from alveolar macrophages and serum levels of sIL-2R are prognostic markers
31. Lymphocytes chemokinetic factors derived from human tonsils: Modulation by 1,25-dihydroxy vitamin D3
32. Immuno-modulating properties of 1,25-dihydroxyvitamin D
33. 1α,25-dihydroxyvitamin D3 inhibits IFNγ synthesis by normal human peripheral blood lymphocytes
34. Th1 and Th2 responses regulate experimental lung granuloma formation
35. Granuloma formation signifies a Th1 cell profile
36. Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis
37. Spontaneous release of IL-2 by lung T-cells in active pulmonary sarcoidosis
38. IFNγ is spontaneously released by alveolar macrophages and T-lymphocytes in patients with pulmonary sarcoidosis
39. Compartmentalized activation of the IL-2 gene by lung T-lymphocytes in active pulmonary sarcoidosis
40. 1,25-Dihydroxycholecalciferol in the pathogenesis of the hypercalcemia of sarcoidosis
41. 3
42. Incomplete suppression of parathyroid hormone activity in sarcoidosis presenting with hypercalcemia
43. 1,25-Dihydroxycholecalciferol in pathogenesis of hypercalcemic sarcoidosis
44. Parathyroid adenoma with coexistent sarcoid granulomas. A hypercalcemic patient
45. Hypercalcemia: Mechanisms, differential diagnosis and remedies
46. A parathyroid hormone-related protein implicated in malignant hypercalcemia: Cloning and expression
47. Parathyroid hormone-related peptide in sarcoidosis
48. Sarcoidosis: Immunopathogenic concepts and their clinical application
49. Ionized calcium and 1,25-dihydroxyvitamin D concentration in the serum of patients with sarcoidosis
50. Management of acute hypercalcemia
51. Clinical impact of bone and calcium changes in sarcoidosis
52. Absence of seasonal variation in serum concentration of 1,25 dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer
53. Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis associated hypercalcemia
54. Characterisation of 1α-hydroxylation of vitamin D sterols by cultured alveolar macrophages from patients with sarcoidosis
55. Corticosteroid therapy suppresses spontaneous IL-2 release and spontaneous proliferation of lung T-lymphocytes in patients with sarcoidosis
56. Hypercalcemia in sarcoidosis
57. Diseases of the parathyroid gland and other disorders
58. Ketoconazole blocks adrenal steroid synthesis
59. Ketoconazole induced reduction in serum 1,25-dihydroxyvitamin D
60. Ketoconazole-induced reduction in serum dihydroxyvitamin D and total serum calcium in hypercalcemic patients
61. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis
62. The tubular maximum for reabsorption in patients with chronic active thoracic sarcoidosis
63. Medical management of nephrolithiasis in Dallas: Update 1987
64. Effect of calcium restriction on renal excretion of oxalate and the probability of stones in the various pathophysiological groups with calcium stones
65. Dietary habits in renal stone patients compared with healthy subjects
66. The influence of diet on urinary risk factors for stones in healthy subjects and idiopathic renal calcium stone formers
67. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones
68. Hyperoxaluria in patients with ileal resection: An abnormality in dietary oxalate absorption
69. Renal oxalate excretion following oral oxalate loads in patients with renal and absorptive hypercalcurias: Effect of calcium and magnesium
70. Calcium oxalate nephrolithiasis: Defective oxalate transport
71. Chlorthalidone reduces the risk of calcium oxalate calculus recurrence, but magnesium hydroxide does not
72. Thiazide prophylaxis of urolithiasis: A double blind study in general practice
73. A UK consensus group on management of glucocorticoid-induced osteoporosis: An update
74. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. American College of Rheumatology. Task Force on Osteoporosis Guidelines
75. Vitamin D and calcium in the prevention of glucocorticoid induced osteoporosis: A 3 year follow up
76. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis
77. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group
78. Prevention of corticosteroid induced osteoporosis with alendronate in sarcoid patients
79. Prevention of corticosteroid induced osteoporosis - a comparison of calcium, calcitriol and calcitonin